Semaglutide studies: 1,194 papers with results
Page 2 of 24
- Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS · Diabetes & metabolism · 2020
Randomized controlled trial · 13 results
- Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
Rodbard HW · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 7 results
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN · The New England journal of medicine · 2023
Randomized controlled trial · 6 results
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M · JAMA · 2017
Randomized controlled trial · 7 results
- Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D · The lancet. Diabetes & endocrinology · 2020
Randomized controlled trial · 28 results
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Rosenstock J · Lancet (London, England) · 2026
Randomized controlled trial · 33 results
- Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
Bliddal H · The New England journal of medicine · 2024
Randomized controlled trial · 6 results
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW · The Journal of clinical endocrinology and metabolism · 2018
Randomized controlled trial · 8 results
- Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y · The lancet. Diabetes & endocrinology · 2024
Randomized controlled trial · 4 results
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Zinman B · Diabetes care · 2019
Randomized controlled trial · 9 results
- Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Seino Y · Diabetes, obesity & metabolism · 2018
Randomized controlled trial · 11 results
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Wharton S · The New England journal of medicine · 2025
Randomized controlled trial · 7 results
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT · Nature medicine · 2022
Randomized controlled trial · 3 results
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T · The lancet. Diabetes & endocrinology · 2022
Randomized controlled trial · 12 results
- Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
Gu W · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 4 results
- Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.
Ambika Gopalakrishnan U · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 8 results
- Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.
Ambika Gopalakrishnan U · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 8 results
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C · The lancet. Diabetes & endocrinology · 2017
Randomized controlled trial · 12 results
- High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.
Aroda VR · Diabetes care · 2025
Randomized controlled trial · 7 results
- Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
Guo L · The lancet. Diabetes & endocrinology · 2026
Randomized controlled trial · 4 results
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.
Dwibedi C · Nature metabolism · 2024
Randomized controlled trial · 7 results
- Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
McGowan BM · The lancet. Diabetes & endocrinology · 2024
Randomized controlled trial · 5 results
- Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D · The New England journal of medicine · 2022
Randomized controlled trial · 10 results
- Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.
Kadowaki T · JAMA internal medicine · 2025
Randomized controlled trial · 4 results
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Yamauchi T · The lancet. Diabetes & endocrinology · 2026
Randomized controlled trial · 13 results
- Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 6 results
- Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.
Ganeshalingam AA · JAMA psychiatry · 2025
Randomized controlled trial · 12 results
- Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lim S · The lancet. Diabetes & endocrinology · 2025
Randomized controlled trial · 9 results
- Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
Wang H · Nature communications · 2025
Randomized controlled trial · 5 results
- Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
Klausen MK · Lancet (London, England) · 2026
Randomized controlled trial · 2 results
- Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 21 results
- Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
Snitker S · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 3 results
- Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
Apperloo EM · Nature medicine · 2025
Randomized controlled trial · 2 results
- Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
Loomba R · The lancet. Gastroenterology & hepatology · 2026
Randomized controlled trial · 9 results
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB · Lancet (London, England) · 2021
Randomized controlled trial · 29 results
- Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.
Chen H · Reproductive biology and endocrinology : RB&E · 2025
Randomized controlled trial · 8 results
- Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
Kapitza C · Diabetologia · 2017
Randomized controlled trial · 7 results
- A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M · Journal of hepatology · 2023
Randomized controlled trial · 4 results
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.
Sass MR · JAMA psychiatry · 2026
Randomized controlled trial · 11 results
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Friedrichsen M · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 12 results
- Semaglutide in Adults with Type 1 Diabetes and Obesity.
Shah VN · NEJM evidence · 2025
Randomized controlled trial · 6 results
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.
Badulescu S · Med (New York, N.Y.) · 2026
Randomized controlled trial · 7 results
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Loomba R · The lancet. Gastroenterology & hepatology · 2023
Randomized controlled trial · 9 results
- Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Stanley C · Nature medicine · 2026
Randomized controlled trial · 4 results
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
Flint A · Alimentary pharmacology & therapeutics · 2021
Randomized controlled trial · 6 results
- Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 9 results
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP · Lancet (London, England) · 2023
Randomized controlled trial · 35 results
- Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.
Gabe MBN · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 8 results
- Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Sivalingam S · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 7 results
- De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
Rodriguez P · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 10 results